Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

NCT04985357 is registered in ClinicalTrials.gov with Travera Inc as lead sponsor.

NCT NCT04985357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04985357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Lead sponsor
Travera Inc
Phase
Observational
Overall status
Withdrawn
Start date
November 30, 2024
Completion date
May 31, 2030
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aml, carcinoma, carcinoma bladder, carcinoma breast, carcinoma cervix, carcinoma of esophagus, carcinoma of lung, carcinoma of the anus, carcinoma of the appendix, carcinoma of the head and neck, carcinoma of the larynx, carcinoma of the lip, carcinoma of the oral cavity, carcinoma of the oropharynx, carcinoma of the paranasal sinus, carcinoma of the penis, carcinoma of the skin, carcinoma of the vulva, carcinoma of unknown primary, carcinoma prostate, carcinoma, ductal, carcinoma, hepatocellular, carcinoma, neuroendocrine, carcinoma, non-small-cell lung, carcinoma, ovarian, carcinoma, pancreatic, carcinoma, renal cell, carcinoma, small cell lung, carcinoma, thymic, cholangiocarcinoma, malignant ascites, malignant pleural effusion, mesothelioma, multiple myeloma in relapse, stage iii breast cancer, stage iii lung cancer, stage iv breast cancer, stage iv lung cancer